- Home
- / Hisamitsu Pharmaceutical
Hisamitsu Pharmaceutical
Revenue
¥163 B
FY, 2026
Hisamitsu Pharmaceutical Summary
Company Summary
- Overview
- Hisamitsu Pharmaceutical (久光製藥株式會社) is a company manufacturing external analgesic and anti-inflammatory preparations, such as medicated plasters, gels, sprays, etc. It develops transdermal anti-inflammatory analgesic drugs, including patches SALONPAS designed to treat pain and stiffness.
- Type
- Public
- Status
- Active
- Founded
- 1847
- HQ
- Tosu, JP | view all locations
- Website
- https://global.hisamitsu/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jim Lepis, Director of Marketing for Hisamitsu America
John Incledon, President and CEO at Hisamitsu America
LocationsView all
26 locations detected
Tosu, Saga HQ
Japan
408 Tashiro Daikancho
Florham Park, NJ
United States
100 Campus Dr #117
Manaus, AM
Brazil
Av. Buriti, 1050 Distrito Industrial
Beijing, Beijing Shi
China
East Ocean Centre, Room 504, 24 Jian Guo Men Wai Avenue
Suzhou, Jiangsu
China
Rm♯, 1805, 18F, No.1 Unit, Suzhou International Wealth Square, No.9 West Suzhou Avenue
Hong Kong, Kowloon
Hong Kong
OfficeE, 9th Floor, MG Tower, No.133 Hoi Bun Road
Hisamitsu Pharmaceutical Financials
Summary Financials
- Revenue (FY, 2026)
- ¥163.0B
- Gross profit (FY, 2026)
- ¥103.2B
- Net income (FY, 2026)
- ¥19.6B
- Cash (FY, 2026)
- ¥108.9B
- EBIT (FY, 2026)
- ¥19.1B